Evidence map›Paper›PMID 11120762›Full record

Trial reportThe Journal of clinical investigation2000

Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men.

A Falahati-Nini, B L Riggs, E J Atkinson, W M O'Fallon, R Eastell, S Khosla

Open access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 254 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
254citing papers in PubMed, 2 pooled it
27.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

254 citing papers in PubMed, 2 syntheses or guidelines pooled it, 754 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men.The Journal of clinical endocrinology and metabolism · 2016
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Regulation of circulating sclerostin levels by sex steroids in women and in men.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011
    Trial
  18. Trial
  19. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010
    Trial
  20. Trial

194 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

A Falahati-NiniEndocrine Research Unit, and. Department of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
B L Riggs
E J Atkinson
W M O'Fallon
R Eastell
S Khosla
Mayo Clinic · USInstitute of Nutrition, Metabolism and Diabetes · CA

Funding

SEX STEROIDS, GROWTH FACTORS, &BONE CELL FUNCTIONP01AG004875 · NIA · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 1985 to 2019
$30.8M
ZESTRIL VS. VERAPAMIL IN THE TREATMENT OF HYPERTENSIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 1985 to 2006
$30.4M
NCRR NIH HHS M01 RR000585NCRR NIH HHS RR00585NIA NIH HHS AG04875NIA NIH HHS P01 AG004875
6 · The paper itself

Abstract

Young adult males who cannot produce or respond to estrogen (E) are osteopenic, suggesting that E may regulate bone turnover in men, as well as in women. Both bioavailable E and testosterone (T) decrease substantially in aging men, but it is unclear which deficiency is the more important factor contributing to the increased bone resorption and impaired bone formation that leads to their bone loss. Thus, we addressed this issue directly by eliminating endogenous T and E production in 59 elderly men (mean age 68 years), studying them first under conditions of physiologic T and E replacement and then assessing the impact on bone turnover of withdrawing both T and E, withdrawing only T, or only E, or continuing both. Bone resorption markers increased significantly in the absence of both hormones and were unchanged in men receiving both hormones. By two-factor ANOVA, E played the major role in preventing the increase in the bone resorption markers, whereas T had no significant effect. By contrast, serum osteocalcin, a bone formation marker, decreased in the absence of both hormones, and both E and T maintained osteocalcin levels. We conclude that in aging men, E is the dominant sex steroid regulating bone resorption, whereas both E and T are important in maintaining bone formation.

Indexed as

AgedAgingAnalysis of VarianceAnthropometryBiomarkersBone DensityBone ResorptionEstrogensHumansMaleOsteocalcinTestosteroneBiomarkersEstrogensOsteocalcinTestosterone

Identifiers

PMID11120762
PMCPMC381474
OpenAlexW2144000500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.